arrow
L

Lorenzo Guglielmetti

negrar di valpolicella
H指数:31
被引数:6,491

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Strengthening tuberculosis clinical trial implementation: operational challenges, lessons learned, and consensus recommendations from a Delphi study

加强结核病临床试验的实施:来自德尔菲研究的运营挑战、经验教训和共识建议

2026-10-010
OAAI
Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence

在对方案组成和依从性的假设干预下,评估丙型肝炎感染对耐多药结核病治疗结果的影响

2026-02-020
OA
Improving Tuberculosis Diagnosis Through Artificial Intelligence (CAD4TB) and Stool Xpert MTB/RIF Testing: A Prospective Study From Oromia, Ethiopia

通过人工智能(CAD4TB)和粪便Xpert MTB/RIF检测改善结核病诊断:来自埃塞俄比亚奥罗米亚地区的前瞻性研究

2026-01-010
PRE
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial

贝达喹啉、德拉马尼、利奈唑胺和氯法齐明用于利福平耐药和氟喹诺酮类耐药结核病(endTB-Q):一项开放标签、多中心、分层、非劣效性、随机对照、III期试验

2025-07-160
PREAI
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study

广泛耐药结核病在欧洲的治疗结局:一项回顾性队列研究

2025-07-150
OA
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

对接触耐多药或耐利福平结核分枝杆菌的个体的管理

2025-06-060
PRE
Recent advances in the treatment of tuberculosis

结核病治疗的最新进展

2024-09-0113
OA
Standards for clinical trials for treating TB
2023-12-013
OAAI
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

结核分枝杆菌分子耐药性检测的临床意义: 2023 TBnet/resist-tb共识声明

2023-04-0126
PRE